The historical rank and industry rank for Beam Therapeutics's FCF Margin % or its related term are showing as below:
MEX:BEAM'
s FCF Margin % Range Over the Past 10 Years
Min: -469561.11 Med: -257.65 Max: -43.37
Current: -236.25
During the past 9 years, the highest FCF Margin % of Beam Therapeutics was -43.37%. The lowest was -469561.11%. And the median was -257.65%.
MEX:BEAM's FCF Margin % is ranked worse than 62.04% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs MEX:BEAM: -236.25
Beam Therapeutics FCF Margin % Related Terms
Beam Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BEAM vs DNLI, ORKA, DYN: FCF Margin % Comparison
For the Biotechnology subindustry, Beam Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (MEX:BEAM) has a FCF Margin % of -411.95% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #595 out of 959 companies in the Biotechnology industry, placing it in the top 62%.
Is Beam Therapeutics' FCF Margin % too high?
Beam Therapeutics' current FCF Margin % is -411.95%. Based on the distribution chart, Beam Therapeutics ranks #595 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' FCF Margin % compare to DNLI and ORKA?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #595 out of 959 companies for FCF Margin %. This places Beam Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current FCF Margin % is -411.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN541.64, compared to a current price of MXN628.46 — trading 16% above its estimated fair value. The current FCF Margin % is -411.95%. Beam Therapeutics' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current FCF Margin % is -411.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 16% above its estimated GF Value™ of MXN541.64.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
FCF Margin %: -411.95%
GF Value™: MXN541.64 vs. price of MXN628.46 (16% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score
Get the complete analysis for MEX:BEAM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
